ABBV
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
Article Summary
HOLD- AbbVie Inc. (NYSE: ABBV) reported disappointing Phase II MIROVA trial results for Elahere, the only FRa-directed antibody-drug conjugate approved for platinum-sensitive ovarian cancer, showing mixed results with a higher confirmed overall response rate of 66.2% versus 32.8% with chemotherapy but a lower median progression-free survival of 9.53 months versus 9.79 months, with the combination having higher toxicity including increased neuropathy and ocular events than chemotherapy alone.
- The MIROVA trial presented at ASCO26 missed its primary endpoint, failing to show Elaheres anticipated benefit in the platinum- sensitive patient population, while the combination failed to improve median PFS at 953 months.
- Safety findings were broadly consistent with prior studies but the combination had higher toxicity, including increased Neuropathy and Ocular Events (HR 1.0; p=0.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 9.5% | 25% | 35.0 ptsBelow Screener (9.5%) - Weak growth |
| EPS Growth Next 5Y ? | 21.5% | 25% | 70.0 ptsGood (21.5%) - Solid outlook |
| Target Price Upside ? | 18.9% | 20% | 60.0 ptsModerate Upside (18.9%) - Target: $253.12 vs Current: $212.93 |
| Gross Margin % ? | 70.6% | 15% | 100.0 ptsExceptional (70.6%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -13.0% | 15% | 40.0 ptsMild Pullback (-13.0%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABBV
- AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
- The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
- It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
- In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.
- Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
- The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.